Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Akari Therapeutics (NQ: AKTX )

1.680 USD -0.020 (-1.18%)
Official Closing Price Updated: 7:58 PM EDT, Oct 23, 2020 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 92,500
Open 1.730
Bid (Size) 1.750 (2)
Ask (Size) 1.770 (5)
Prev. Close 1.700
Today's Range 1.680 - 1.740
52wk Range 0.8700 - 2.790
Shares Outstanding 15,256,933
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Akari Therapeutics Announces Further Clinical Trial Progress Using Nomacopan to Treat COVID-19 Pneumonia
From GlobeNewswire News Releases
Akari Therapeutics Announces Successful Scientific Advice Meeting with the European Medicines Agency (EMA) Establishing a Clear Path in Both U.S. and Europe for a Pivotal Phase III Study of Nomacopan
From GlobeNewswire News Releases

Performance

YTD
-3.45%
-3.45%
1 Month
+0.60%
+0.60%
3 Month
-13.85%
-13.85%
6 Month
-0.59%
-0.59%
1 Year
-4.00%
-4.00%

More News

Read More
Akari Therapeutics to Present Its Phase III Plans at the International Pemphigus & Pemphigoid Foundation (IPPF) Patient Education Conference
From GlobeNewswire News Releases
Akari Therapeutics to Participate in Two September Virtual Investor Conferences
From GlobeNewswire News Releases
Akari Therapeutics Reports Second Quarter 2020 Financial Results and Highlights Recent Clinical Progress
From GlobeNewswire News Releases
Akari Therapeutics Announces International Clinical Development Program of Nomacopan for the Potential Treatment of COVID-19 Pneumonia
From GlobeNewswire News Releases
Akari Therapeutics Announces Successful End-of-Phase II Meeting With FDA to Initiate Pivotal Phase III Study for Treatment of Bullous Pemphigoid With Nomacopan
From GlobeNewswire News Releases
Akari Therapeutics Enters into a Securities Purchase Agreement for up to $30 Million with Aspire Capital Fund, LLC
From GlobeNewswire News Releases
Akari Therapeutics Announces Appointment of Chief Financial Officer
From GlobeNewswire News Releases
Akari Therapeutics Reports First Quarter 2020 Financial Results and Highlights Recent Clinical Progress
From GlobeNewswire News Releases
Akari Therapeutics Receives Positive EMA Opinion on Orphan Designation for Nomacopan for Bullous Pemphigoid
From GlobeNewswire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.